KESTRA MEDICAL TECHNOLOGIES, LTD.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $KMTS in the last 7 days.
Kestra Medical Technologies reported Q1 FY2027 revenue of $31.0M, beating estimates by $1.4M, but GAAP EPS loss widened to $0.75. Revenue grew 60% YoY, gross margin expanded to 56.5%, and FY2027 guidance was raised to $141.0M. Net loss increased to $44.1M, and cash burn rose. The stock initially fell but later gained 4.74%.
Kestra Medical Technologies (KMTS) reported a 60% revenue increase to $31.0M in Q1 2027, with gross margin rising to 56.5%. The company raised fiscal 2027 revenue guidance to $141M. Gross profit nearly doubled, but operating losses widened to $37.7M due to higher expenses. The company's cash position decreased slightly, with $244.7M remaining.
Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.
Recent KMTS coverage spans earnings, insider activity and financial news.
In the last 30 days, KMTS insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($609K). The most active reporter was Reilly Kevin C with 1 filing.
No new catalyst; price move already reflected.
Revenue guidance raise may support short‑term upside; operating loss remains large, risk of cash burn.
Guidance raise and margin expansion suggest upside potential, but higher operating expenses and near‑term cash burn temper enthusiasm.
The earnings miss and widening loss suggest short‑term pressure on the stock.
Positive earnings surprise and higher guidance suggest upside potential.
AlphAI scores every news story that mentions KMTS with an AI model for sentiment and relevance, and aggregates insider trades from KESTRA MEDICAL TECHNOLOGIES, LTD.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kestra Medical Technologies reported Q1 FY2027 revenue of $31.0M, beating estimates by $1.4M, but GAAP EPS loss widened to $0.75. Revenue grew 60% YoY, gross margin expanded to 56.5%, and FY2027 guidance was raised to $141.0M. Net loss increased to $44.1M, and cash burn rose. The stock initially fell but later gained 4.74%.
2 min readKestra Medical Technologies (KMTS) reported a 60% revenue increase to $31.0M in Q1 2027, with gross margin rising to 56.5%. The company raised fiscal 2027 revenue guidance to $141M. Gross profit nearly doubled, but operating losses widened to $37.7M due to higher expenses. The company's cash position decreased slightly, with $244.7M remaining.
2 min readKestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.
3 min readKestra Medical Technologies reported Q1 2027 revenue of $30.97M, up 60% YoY, but a net loss of $(44.09)M. Diluted EPS was $(0.75). Growth was driven by increased use of its ASSURE® wearable cardiac defibrillator, with revenue primarily from Medicare, Medicaid, and private payors. The company expanded sales and marketing and improved operational efficiency.
1 min readKESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported
2 min readHanley Conor sold 5,694 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $25.25 ($0.14M total) on 2026-09-08.
1 min readKESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The Kestra Medical Technologies, Ltd. (the “Company”) 2026 annual general meeting of shareholders (the “2026 Annual Meeting”) was held on September 9, 2026. The total number of the Company’s common shares voted in per
1 min readMorgan Stanley downgraded Apple (AAPL) to Underperform, citing supply-chain checks that Apple cancelled a 20th anniversary all-glass iPhone model; price target cut to $263.66 from $285.56. It upgraded HPE to Overweight, PT $69 (from $71), and NetApp to Equal Weight, PT $173 (from $137). Other analyst actions included upgrades to Qualcomm, SanDisk, Dick’s Sporting, and Everpure, plus downgrades to Teradata, Akamai, Doximity, and Spectrum Brands.
4 min readMahboob Vaseem (Chief Financial Officer) sold 26,287 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $25.88 ($25.87–$26.33, $0.68M total) across 2 trades on 2026-08-07 under a Rule 10b5-1 trading plan.
2 min readAnalyst actions on Monday included Bank of America reiterating Nvidia as Buy ahead of earnings, with ~16x CY27 forward P/E. Loop raised FirstCash Holdings to Buy, PT $255, and cut Domino’s to Hold, PT $353. UBS reiterated Micron Buy, PT $1,625. Jefferies downgraded Apple to underperform. Citi reiterated SpaceX Buy, PT $200. Bernstein raised Microsoft PT to $660.
2 min read
